Joint response by HAI, ISDB and MiEF to a WHO public consultation. The WHO proposal to assign a "biological qualifier" after the International Nonproprietary Name (INN) of glycosylated biosimilars offers an acceptable solution at global level.
Category: Campaigns
A step backwards on pharmaceutical policy at the EU Commission: the move to directorate general (DG) Enterprise and Industry is unacceptable
Joint open letter to President Juncker by 28 organisations. Promoting profit over public health puts European citizens at risk. No, medicinal products are not just a commodity like any other.
Attachment: 20140916openletterpharmapolicy.pdf
EMA’s policy on pharmacovigilance: access to qualitative data is needed, pharmacovigilance data are not “trade secrets”
Joint response to the EMA consultation by the Cochrane AEMG, HAI Europe, ISDB and MiEF. “Protection of personal data” must not be used as a pretext to strengthen intellectual property over pharmacovigilance data.
Attachment: 20140915jointresponseaccesspolicy.pdf
Clinical trial data disclosure protects the public from preventable harm
In their Joint Response to a consultation by the US Institute of Medicine (IOM), HAI Europe, ISDB, MiEF and TACD encourage the active implementation of a data sharing policy that ensures full public access to clinical data in the US, in alignment with the new European requirements.
The US-EU Trade Agreement Proposals by the pharmaceutical industry undermine European public policy making and public health
A report by the civil society partners shows that the pharmaceutical industry's wish list for the Transatlantic Trade and Investment Partnership (TTIP) is detrimental for public health, will increase the cost of medicines and undermines democratic processes.